114 related articles for article (PubMed ID: 17855184)
1. Economic evaluation of linezolid versus teicoplanin for the treatment of infections caused by gram-positive microorganisms in Spain.
Grau S; Aguado JM; Mateu-de Antonio J; Gonzalez P; Del Castillo A
J Chemother; 2007 Aug; 19(4):398-409. PubMed ID: 17855184
[TBL] [Abstract][Full Text] [Related]
2. Pharmacoeconomic evaluation of linezolid versus teicoplanin in bacteremia by Gram-positive microorganisms.
Grau S; Mateu-de Antonio J; Soto J; Marín-Casino M; Salas E
Pharm World Sci; 2005 Dec; 27(6):459-64. PubMed ID: 16341954
[TBL] [Abstract][Full Text] [Related]
3. Hospital resource use and cost of treatment with linezolid versus teicoplanin for treatment of serious gram-positive bacterial infections among hospitalized patients from South America and Mexico: results from a multicenter trial.
López H; Li JZ; Balan DA; Willke RJ; Rittenhouse BE; Mozaffari E; Vidal G; Zitto T; Tang T
Clin Ther; 2003 Jun; 25(6):1846-71. PubMed ID: 12860502
[TBL] [Abstract][Full Text] [Related]
4. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections.
Wilcox M; Nathwani D; Dryden M
J Antimicrob Chemother; 2004 Feb; 53(2):335-44. PubMed ID: 14729745
[TBL] [Abstract][Full Text] [Related]
5. An economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in serious Gram-positive bacterial infections: the importance of treatment setting in evaluating treatment effects.
Nathwani D; Li JZ; Balan DA; Willke RJ; Rittenhouse BE; Mozaffari E; Tavakoli M; Tang T
Int J Antimicrob Agents; 2004 Apr; 23(4):315-24. PubMed ID: 15081078
[TBL] [Abstract][Full Text] [Related]
6. Linezolid treatment for gram-positive infections: a retrospective comparison with teicoplanin.
Tascini C; Gemignani G; Doria R; Biancofiore G; Urbani L; Mosca C; Malacarne P; Papineschi F; Passaglia C; Dal Canto L; Procaccini M; Furneri G; Didoni G; Filipponi F; Menichetti F
J Chemother; 2009 Jun; 21(3):311-6. PubMed ID: 19567352
[TBL] [Abstract][Full Text] [Related]
7. Cost-minimization analysis and audit of antibiotic management of bone and joint infections with ambulatory teicoplanin, in-patient care or outpatient oral linezolid therapy.
Nathwani D; Barlow GD; Ajdukiewicz K; Gray K; Morrison J; Clift B; France AJ; Davey P
J Antimicrob Chemother; 2003 Feb; 51(2):391-6. PubMed ID: 12562708
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of linezolid and vancomycin in the treatment of surgical site infections.
Patanwala AE; Erstad BL; Nix DE
Curr Med Res Opin; 2007 Jan; 23(1):185-93. PubMed ID: 17257479
[TBL] [Abstract][Full Text] [Related]
9. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
McKinnon PS; Sorensen SV; Liu LZ; Itani KM
Ann Pharmacother; 2006 Jun; 40(6):1017-23. PubMed ID: 16720705
[TBL] [Abstract][Full Text] [Related]
10. Pharmacoeconomics of linezolid.
Grau S; Rubio-Terrés C
Expert Opin Pharmacother; 2008 Apr; 9(6):987-1000. PubMed ID: 18377341
[TBL] [Abstract][Full Text] [Related]
11. Linezolid: a pharmacoeconomic review of its use in serious Gram-positive infections.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2005; 23(9):945-64. PubMed ID: 16153136
[TBL] [Abstract][Full Text] [Related]
12. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study.
Cepeda JA; Whitehouse T; Cooper B; Hails J; Jones K; Kwaku F; Taylor L; Hayman S; Shaw S; Kibbler C; Shulman R; Singer M; Wilson AP
J Antimicrob Chemother; 2004 Feb; 53(2):345-55. PubMed ID: 14711840
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using Bayesian methods for evidence synthesis.
Bounthavong M; Zargarzadeh A; Hsu DI; Vanness DJ
Value Health; 2011; 14(5):631-9. PubMed ID: 21839399
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of linezolid versus vancomycin for hospitalized patients with complicated skin and soft-tissue infections in France.
De Cock E; Sorensen S; Levrat F; Besnier JM; Dupon M; Guery B; Duttagupta S
Med Mal Infect; 2009 May; 39(5):330-40. PubMed ID: 19304423
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of linezolid vs vancomycin in suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany.
De Cock E; Krueger WA; Sorensen S; Baker T; Hardewig J; Duttagupta S; Müller E; Piecyk A; Reisinger E; Resch A
Infection; 2009 Apr; 37(2):123-32. PubMed ID: 19277465
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of the treatment of ventilator-associated pneumonia with linezolid or vancomycin in Spain.
Grau S; Alvarez-Lerma F; del Castillo A; Neipp R; Rubio-Terrés C
J Chemother; 2005 Apr; 17(2):203-11. PubMed ID: 15920907
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of teicoplanin and linezolid therapies in patients with methicillin-resistant Staphylococcus aureus pneumonia acquired from respiratory intensive care unit].
Taşbakan MS; Korkmaz Ekren P; Pullukçu H; Başarık B; Susur A; Aydemir S; Başoğlu OK; Bacakoğlu F
Mikrobiyol Bul; 2010 Jul; 44(3):357-66. PubMed ID: 21063985
[TBL] [Abstract][Full Text] [Related]
18. Linezolid: the first oxazolidinone antimicrobial.
Lindley DA
Ann Intern Med; 2003 Nov; 139(10):863; author reply 864. PubMed ID: 14623625
[No Abstract] [Full Text] [Related]
19. Linezolid: implications for neurosurgical infections.
Nguyen CM; Larive LL; Rhoney DH
Neurol Res; 2003 Jan; 25(1):22-6. PubMed ID: 12564121
[TBL] [Abstract][Full Text] [Related]
20. Linezolid for the treatment of serious gram-positive infections.
McAuley L
Issues Emerg Health Technol; 2001 Mar; (15):1-6. PubMed ID: 11902223
[No Abstract] [Full Text] [Related]
[Next] [New Search]
